Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iHIVARNA-01 in Chronically HIV-infected Patients
NCT02413645Phase 1Completed
- Sponsor
- Judit Pich Martínez
- Start
- Jun 2015
- Primary completion
- Jun 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of iHIVARNA-01 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Judit Pich Martínez. Primary endpoint: Dose Limiting Toxicity at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
iHIVARNA-01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02413645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413645.